The FDA approved the pill Zuranolone, developed by Sage and Biogen, for postpartum depression but declined to approve it for major depressive disorder.
The FDA's approval late Friday made Zuranolone the first oral treatment for
But the FDA said they did not provide enough evidence of the drug's effectiveness in treating the condition, which affects a much larger population of patients., or about 7% of the people ages 18 and older, in a given year. He said clinical depression "was really the big upside driver here" for the companies, while postpartum depression is "much smaller and may not be hugely profitable."
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Biogen, Sage face uphill battle with postpartum depression pillThe U.S. drug regulator's approval of Biogen and Sage Therapeutics' first-of-its-kind postpartum depression (PPD) pill is unlikely to allay the drugmakers' growth concerns, analysts said on Monday.
Read more »
FDA approves first postpartum depression pill in the USThe US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression.
Read more »
FDA approves first postpartum depression pill in the USThe US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression.
Read more »
FDA approves first postpartum depression pill in the USThe US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression.
Read more »
FDA approves first postpartum depression pill in the USThe US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression.
Read more »
FDA approves first postpartum depression pill in the USThe US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression.
Read more »